Skip to main content
SpringerLink
Log in
Book cover

Genetically Engineered Mice for Cancer Research pp 443–463Cite as

Utilizing Mouse Models of Human Cancer for Assessing Immune Modulation of Cancer Development

  • Chapter
  • First Online:

  • 1334 Accesses

Abstract

The availability and diversity of mouse models of human cancer that develop organ-specific neoplasms has increased significantly in the past 10 years. These, coupled with mouse strains where components of the immune system have been manipulated or deleted, have provided novel insights into how immune cells and immune function significantly contributes to cancer development. Herein, we review relevant literature, where mouse models of human cancer development have provided novel insights into mechanisms of pro- versus antitumor immunity.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, Nakanishi K, Akira S (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9:143–150

    PubMed  CAS  Google Scholar 

  • Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511

    PubMed  CAS  Google Scholar 

  • Albini A, Sporn MB (2007) The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7:139–147

    PubMed  CAS  Google Scholar 

  • Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732–738

    PubMed  CAS  Google Scholar 

  • Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678–689

    PubMed  CAS  Google Scholar 

  • Arbeit JM, Munger K, Howley PM, Hanahan D (1994) Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 68:4358–4368

    PubMed  CAS  Google Scholar 

  • Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355:885–895

    PubMed  CAS  Google Scholar 

  • Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR (2004) Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene 23:1902–1910

    PubMed  CAS  Google Scholar 

  • Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217

    PubMed  CAS  Google Scholar 

  • Beck BN, Henney CS (1981) An analysis of the natural killer cell defect in beige mice. Cell Immunol 61:343–352

    PubMed  CAS  Google Scholar 

  • Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23:201–208

    PubMed  CAS  Google Scholar 

  • Bennett CL, Clausen BE (2007) DC ablation in mice: promises, pitfalls, and challenges. Trends Immunol 28:525–531

    PubMed  CAS  Google Scholar 

  • Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z et al (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744

    PubMed  CAS  Google Scholar 

  • Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873–884

    PubMed  CAS  Google Scholar 

  • Bhowmick NA, Moses HL (2005) Tumor-stroma interactions. Curr Opin Genet Dev 15:97–101

    PubMed  CAS  Google Scholar 

  • Borriello F, Sethna MP, Boyd SD, Schweitzer AN, Tivol EA, Jacoby D, Strom TB, Simpson EM, Freeman GJ, Sharpe AH (1997) B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6:303–313

    PubMed  CAS  Google Scholar 

  • Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2:373–382

    PubMed  CAS  Google Scholar 

  • Bosma GC, Custer RP, Bosma MJ (1983) A severe combined immunodeficiency mutation in the mouse. Nature 301:527–530

    PubMed  CAS  Google Scholar 

  • Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19:56–59

    PubMed  CAS  Google Scholar 

  • Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G (2008) Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 14:28–36

    PubMed  CAS  Google Scholar 

  • Buell JF, Gross TG, Woodle ES (2005) Malignancy after transplantation. Transplantation 80:S254–S264

    PubMed  Google Scholar 

  • Carroll MC (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981–986

    PubMed  CAS  Google Scholar 

  • Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299–309

    PubMed  CAS  Google Scholar 

  • Cha YI, DuBois RN (2007) NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 58:239–252

    PubMed  CAS  Google Scholar 

  • Chambers CA, Cado D, Truong T, Allison JP (1997) Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci USA 94:9296–9301

    PubMed  CAS  Google Scholar 

  • Chen J, Trounstine M, Alt FW, Young F, Kurahara C, Loring JF, Huszar D (1993) Immunoglobulin gene rearrangement in B cell deficient mice generated by targeted deletion of the JH locus. Int Immunol 5:647–656

    PubMed  CAS  Google Scholar 

  • Choudhury A, Mosolits S, Kokhaei P, Hansson L, Palma M, Mellstedt H (2006) Clinical results of vaccine therapy for cancer: learning from history for improving the future. Adv Cancer Res 95:147–202

    PubMed  CAS  Google Scholar 

  • Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705–4708

    PubMed  CAS  Google Scholar 

  • Colombo MP, Piconese S (2007) Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7:880–887

    PubMed  CAS  Google Scholar 

  • Coussens LM, Hanahan D, Arbeit JM (1996) Genetic predisposition and parameters of malignant progression in K14- HPV16 transgenic mice. Am J Pathol 149:1899–1917

    PubMed  CAS  Google Scholar 

  • Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382–1397

    PubMed  CAS  Google Scholar 

  • Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481–490

    PubMed  CAS  Google Scholar 

  • Croci DO, Zacarias Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG (2007) Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 56:1687–1700

    PubMed  Google Scholar 

  • Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M (1997) Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623–1626

    PubMed  CAS  Google Scholar 

  • Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017–1028

    PubMed  CAS  Google Scholar 

  • Dannenberg A, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 4:431–436

    PubMed  CAS  Google Scholar 

  • De Giorgi U, Pupi A, Turrisi G, Montenora I, Morini S, Fayyaz M, De Simone M, Fiorentini G (2007) Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor. Rev Recent Clin Trials 2:43–48

    PubMed  Google Scholar 

  • De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, Naldini L (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8:211–226

    PubMed  Google Scholar 

  • de Visser KE, Korets LV, Coussens LM (2004) Early neoplastic progression is complement independent. Neoplasia 6:768–776

    PubMed  Google Scholar 

  • de Visser KE, Korets LV, Coussens LM (2005) De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411–423

    PubMed  Google Scholar 

  • de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6:24–37

    PubMed  Google Scholar 

  • Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM et al (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378:406–409

    PubMed  CAS  Google Scholar 

  • Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91:1–30

    PubMed  CAS  Google Scholar 

  • Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP (2005) Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56–65

    PubMed  CAS  Google Scholar 

  • Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998

    PubMed  CAS  Google Scholar 

  • Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148

    PubMed  CAS  Google Scholar 

  • Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836–848

    PubMed  CAS  Google Scholar 

  • Duttlinger R, Manova K, Chu TY, Gyssler C, Zelenetz AD, Bachvarova RF, Besmer P (1993) W-sash affects positive and negative elements controlling c-kit expression: ectopic c-kit expression at sites of kit-ligand expression affects melanogenesis. Development 118:705–717

    PubMed  CAS  Google Scholar 

  • Ebnet K, Hausmann M, Lehmann-Grube F, Mullbacher A, Kopf M, Lamers M, Simon MM (1995) Granzyme A-deficient mice retain potent cell-mediated cytotoxicity. EMBO J 14:4230–4239

    PubMed  CAS  Google Scholar 

  • Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, Mihm M, Dranoff G (2003) Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 197:1213–1219

    PubMed  CAS  Google Scholar 

  • Feuillet V, Medjane S, Mondor I, Demaria O, Pagni PP, Galan JE, Flavell RA, Alexopoulou L (2006) Involvement of Toll-like receptor 5 in the recognition of flagellated bacteria. Proc Natl Acad Sci USA 103:12487–12492

    PubMed  CAS  Google Scholar 

  • Finke J, Ferrone S, Frey A, Mufson A, Ochoa A (1999) Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 20:158–160

    PubMed  CAS  Google Scholar 

  • Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M et al (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131:463–475

    PubMed  CAS  Google Scholar 

  • Freeman GJ, Borriello F, Hodes RJ, Reiser H, Hathcock KS, Laszlo G, McKnight AJ, Kim J, Du L, Lombard DB et al (1993) Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907–909

    PubMed  CAS  Google Scholar 

  • Frese KK, Tuveson DA (2007) Maximizing mouse cancer models. Nat Rev Cancer 7:645–658

    PubMed  CAS  Google Scholar 

  • Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ et al (2007) Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:1869–1881

    PubMed  CAS  Google Scholar 

  • Fung-Leung WP, Schilham MW, Rahemtulla A, Kundig TM, Vollenweider M, Potter J, van Ewijk W, Mak TW (1991) CD8 is needed for development of cytotoxic T cells but not helper T cells. Cell 65:443–449

    PubMed  CAS  Google Scholar 

  • Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964

    PubMed  CAS  Google Scholar 

  • Garbe AI, Vermeer B, Gamrekelashvili J, von Wasielewski R, Greten FR, Westendorf AM, Buer J, Schmid RM, Manns MP, Korangy F et al (2006) Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res 66:508–516

    PubMed  CAS  Google Scholar 

  • Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC (2001) Regulation of cutaneous malignancy by gammadelta T cells. Science 294:605–609

    PubMed  CAS  Google Scholar 

  • Girardi M, Glusac E, Filler RB, Roberts SJ, Propperova I, Lewis J, Tigelaar RE, Hayday AC (2003) The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. J Exp Med 198:747–755

    PubMed  CAS  Google Scholar 

  • Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114:623–633

    PubMed  CAS  Google Scholar 

  • Goldrath AW, Bevan MJ (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402:255–262

    PubMed  CAS  Google Scholar 

  • Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K et al (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci USA 104:19977–19982

    PubMed  CAS  Google Scholar 

  • Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118:285–296

    PubMed  CAS  Google Scholar 

  • Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ (2005) Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 167:835–848

    PubMed  CAS  Google Scholar 

  • Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67

    PubMed  Google Scholar 

  • Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M (2007) Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11:291–302

    PubMed  CAS  Google Scholar 

  • Gupta RA, Dubois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1:11–21

    PubMed  CAS  Google Scholar 

  • Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70

    PubMed  CAS  Google Scholar 

  • Hanahan D, Wagner EF, Palmiter RD (2007) The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev 21:2258–2270

    PubMed  CAS  Google Scholar 

  • Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA, Schmidt RE, Sandor M, Capel PJ, Daeron M et al (1996) Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity 5:181–188

    PubMed  CAS  Google Scholar 

  • Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K et al (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408:740–745

    PubMed  CAS  Google Scholar 

  • Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196–200

    PubMed  CAS  Google Scholar 

  • Hennings H, Glick AB, Greenhalgh DA, Morgan DL, Strickland JE, Tennenbaum T, Yuspa SH (1993) Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. Proc Soc Exp Biol Med 202:1–8

    PubMed  CAS  Google Scholar 

  • Heusel JW, Wesselschmidt RL, Shresta S, Russell JH, Ley TJ (1994) Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76:977–987

    PubMed  CAS  Google Scholar 

  • Hopken UE, Lu B, Gerard NP, Gerard C (1996) The C5a chemoattractant receptor mediates mucosal defence to infection. Nature 383:86–89

    PubMed  CAS  Google Scholar 

  • Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162:3749–3752

    PubMed  CAS  Google Scholar 

  • Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD, Newman RA, Yang P, Thaler HT, Muller WJ et al (2005) HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res 65:10113–10119

    PubMed  CAS  Google Scholar 

  • Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA (1984) Functional T cells in athymic nude mice. Proc Natl Acad Sci USA 81:886–888

    PubMed  CAS  Google Scholar 

  • Imada A, Shijubo N, Kojima H, Abe S (2000) Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. Eur Respir J 15:1087–1093

    PubMed  CAS  Google Scholar 

  • Itohara S, Mombaerts P, Lafaille J, Iacomini J, Nelson A, Clarke AR, Hooper ML, Farr A, Tonegawa S (1993) T cell receptor delta gene mutant mice: independent generation of alpha beta T cells and programmed rearrangements of gamma delta TCR genes. Cell 72:337–348

    PubMed  CAS  Google Scholar 

  • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62

    PubMed  CAS  Google Scholar 

  • Jain RK (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8:309–316

    PubMed  CAS  Google Scholar 

  • Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197–216

    PubMed  CAS  Google Scholar 

  • Janeway CA, Travers P, Walport M, Shlomchik M (2001) Immunobiology, 5th edn. Garland Publishing, New York

    Google Scholar 

  • Johansson M, Denardo DG, Coussens LM (2008) Polarized immune responses differentially regulate cancer development. Immunol Rev 222:145–154

    PubMed  CAS  Google Scholar 

  • Jonkers J, Derksen PW (2007) Modeling metastatic breast cancer in mice. J Mammary Gland Biol Neoplasia 12:191–203

    PubMed  Google Scholar 

  • Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7:513–520

    PubMed  CAS  Google Scholar 

  • Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F et al (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211–220

    PubMed  CAS  Google Scholar 

  • Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ, Podack ER, Zinkernagel RM, Hengartner H (1994) Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31–37

    PubMed  CAS  Google Scholar 

  • Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556–7561

    PubMed  CAS  Google Scholar 

  • Karin M (2006) NF-kappaB and cancer: mechanisms and targets. Mol Carcinog 45:355–361

    PubMed  CAS  Google Scholar 

  • Kim CF, Jackson EL, Kirsch DG, Grimm J, Shaw AT, Lane K, Kissil J, Olive KP, Sweet-Cordero A, Weissleder R et al (2005) Mouse models of human non-small-cell lung cancer: raising the bar. Cold Spring Harb Symp Quant Biol 70:241–250

    PubMed  CAS  Google Scholar 

  • Kitamura Y, Go S, Hatanaka K (1978) Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447–452

    PubMed  CAS  Google Scholar 

  • Kitamura D, Roes J, Kuhn R, Rajewsky K (1991) A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 350:423–426

    PubMed  CAS  Google Scholar 

  • Klein S, McCormick F, Levitzki A (2005) Killing time for cancer cells. Nat Rev Cancer 5:573–580

    PubMed  CAS  Google Scholar 

  • Koller BH, Marrack P, Kappler JW, Smithies O (1990) Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science 248:1227–1230

    PubMed  CAS  Google Scholar 

  • Kontgen F, Suss G, Stewart C, Steinmetz M, Bluethmann H (1993) Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int Immunol 5:957–964

    PubMed  CAS  Google Scholar 

  • Kusmartsev S, Gabrilovich DI (2006) Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25:323–331

    PubMed  CAS  Google Scholar 

  • Kwon BS, Hurtado JC, Lee ZH, Kwack KB, Seo SK, Choi BK, Koller BH, Wolisi G, Broxmeyer HE, Vinay DS (2002) Immune responses in 4-1BB (CD137)-deficient mice. J Immunol 168:5483–5490

    PubMed  CAS  Google Scholar 

  • Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD et al (1995) Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83:483–492

    PubMed  CAS  Google Scholar 

  • Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M (2006) IL-23 promotes tumour incidence and growth. Nature 442:461–465

    PubMed  CAS  Google Scholar 

  • Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL (1996) Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 56:4625–4629

    PubMed  CAS  Google Scholar 

  • Lin EY, Nguyen AV, Russell RG, Pollard JW (2001) Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193:727–740

    PubMed  CAS  Google Scholar 

  • Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA, Karin M (2007) Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446:690–694

    PubMed  CAS  Google Scholar 

  • Luster AD (2002) The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol 14:129–135

    PubMed  CAS  Google Scholar 

  • Marks SC Jr, Lane PW (1976) Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J Hered 67:11–18

    PubMed  Google Scholar 

  • McHeyzer-Williams MG (2003) B cells as effectors. Curr Opin Immunol 15:354–361

    PubMed  CAS  Google Scholar 

  • Molina H, Holers VM, Li B, Fung Y, Mariathasan S, Goellner J, Strauss-Schoenberger J, Karr RW, Chaplin DD (1996) Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 93:3357–3361

    PubMed  CAS  Google Scholar 

  • Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869–877

    PubMed  CAS  Google Scholar 

  • Mombaerts P, Arnoldi J, Russ F, Tonegawa S, Kaufmann SH (1993) Different roles of alpha beta and gamma delta T cells in immunity against an intracellular bacterial pathogen. Nature 365:53–56

    PubMed  CAS  Google Scholar 

  • Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M et al (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5:828–831

    PubMed  CAS  Google Scholar 

  • Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA et al (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83:473–482

    PubMed  CAS  Google Scholar 

  • Murphy JE, Robert C, Kupper TS (2000) Interleukin-1 and cutaneous inflammation: a crucial link between innate and acquired immunity. J Invest Dermatol 114:602–608

    PubMed  CAS  Google Scholar 

  • Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287–309

    PubMed  CAS  Google Scholar 

  • Nozawa H, Chiu C, Hanahan D (2006) Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci USA 103:12493–12498

    PubMed  CAS  Google Scholar 

  • Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87:803–809

    PubMed  CAS  Google Scholar 

  • Ostrand-Rosenberg S (2008) Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 18:11–18

    PubMed  CAS  Google Scholar 

  • Persano L, Crescenzi M, Indraccolo S (2007) Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28:87–114

    PubMed  CAS  Google Scholar 

  • Peto J (2001) Cancer epidemiology in the last century and the next decade. Nature 411:390–395

    PubMed  CAS  Google Scholar 

  • Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461–466

    PubMed  CAS  Google Scholar 

  • Qin Z, Blankenstein T (2004) A cancer immunosurveillance controversy. Nat Immunol 5:3–4

    PubMed  CAS  Google Scholar 

  • Rahemtulla A, Fung-Leung WP, Schilham MW, Kundig TM, Sambhara SR, Narendran A, Arabian A, Wakeham A, Paige CJ, Zinkernagel RM et al (1991) Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353:180–184

    PubMed  CAS  Google Scholar 

  • Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, Girardi M (2007) Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci USA 104:6770–6775

    PubMed  CAS  Google Scholar 

  • Sawyers C (2004) Targeted cancer therapy. Nature 432:294–297

    PubMed  CAS  Google Scholar 

  • Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53:64–72

    PubMed  CAS  Google Scholar 

  • Shahinian A, Pfeffer K, Lee KP, Kundig TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW (1993) Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609–612

    PubMed  CAS  Google Scholar 

  • Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111

    PubMed  CAS  Google Scholar 

  • Shinkai Y, Rathbun G, Lam KP, Oltz EM, Stewart V, Mendelsohn M, Charron J, Datta M, Young F, Stall AM et al (1992) RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 68:855–867

    PubMed  CAS  Google Scholar 

  • Sinnamon MJ, Carter KJ, Sims LP, Lafleur B, Fingleton B, Matrisian LM (2008) A protective role for mast cells in intestinal tumorigenesis. Carcinogenesis 29(4):880–886

    PubMed  CAS  Google Scholar 

  • Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, Kawano T, Pelikan SB, Crowe NY, Godfrey DI (2000) Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 191:661–668

    PubMed  CAS  Google Scholar 

  • Smyth MJ, Crowe NY, Godfrey DI (2001) NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 13:459–463

    PubMed  CAS  Google Scholar 

  • Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI (2007) Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13:1211–1218

    PubMed  CAS  Google Scholar 

  • Sprent J, Surh CD (2002) T cell memory. Annu Rev Immunol 20:551–579

    PubMed  CAS  Google Scholar 

  • Street SE, Zerafa N, Iezzi M, Westwood JA, Stagg J, Musiani P, Smyth MJ (2007) Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma. Cancer Res 67:5454–5460

    PubMed  CAS  Google Scholar 

  • Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137–1146

    PubMed  CAS  Google Scholar 

  • Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ (2008) Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 105:652–656

    PubMed  CAS  Google Scholar 

  • Tabi Z, Man S (2006) Challenges for cancer vaccine development. Adv Drug Deliv Rev 58:902–915

    PubMed  CAS  Google Scholar 

  • Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969–976

    PubMed  CAS  Google Scholar 

  • Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV (1994) FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 76:519–529

    PubMed  CAS  Google Scholar 

  • Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira S (1999) Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11:443–451

    PubMed  CAS  Google Scholar 

  • Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S (2001) Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 13:933–940

    PubMed  CAS  Google Scholar 

  • Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S (2002) Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169:10–14

    PubMed  CAS  Google Scholar 

  • Taylor PR, Nash JT, Theodoridis E, Bygrave AE, Walport MJ, Botto M (1998) A targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45. J Biol Chem 273:1699–1704

    PubMed  CAS  Google Scholar 

  • Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, Sessoms A, Dunson DB, Rogan EG, Morham SG, Smart RC et al (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395–3401

    PubMed  CAS  Google Scholar 

  • Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302:575–581

    PubMed  CAS  Google Scholar 

  • Turini ME, DuBois RN (2002) Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35–37

    PubMed  CAS  Google Scholar 

  • Tuveson DA, Jacks T (2002) Technologically advanced cancer modeling in mice. Curr Opin Genet Dev 12:105–110

    PubMed  CAS  Google Scholar 

  • van den Broek ME, Kagi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H (1996) Decreased tumor surveillance in perforin-deficient mice. J Exp Med 184:1781–1790

    PubMed  Google Scholar 

  • Van Dyke T, Jacks T (2002) Cancer modeling in the modern era: progress and challenges. Cell 108:135–144

    PubMed  Google Scholar 

  • Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S (1992) TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 71:1205–1214

    PubMed  Google Scholar 

  • van Kempen LC, de Visser KE, Coussens LM (2006) Inflammation, proteases and cancer. Eur J Cancer 42:728–734

    PubMed  Google Scholar 

  • Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174:83–93

    PubMed  Google Scholar 

  • Walport MJ (2001a) Complement. First of two parts. N Engl J Med 344:1058–1066

    PubMed  CAS  Google Scholar 

  • Walport MJ (2001b) Complement. Second of two parts. N Engl J Med 344:1140–1144

    PubMed  CAS  Google Scholar 

  • Wedemeyer J, Galli SJ (2005) Decreased susceptibility of mast cell-deficient Kit(W)/Kit(W-v) mice to the development of 1, 2-dimethylhydrazine-induced intestinal tumors. Lab Invest 85:388–396

    PubMed  CAS  Google Scholar 

  • Wessels MR, Butko P, Ma M, Warren HB, Lage AL, Carroll MC (1995) Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 92:11490–11494

    PubMed  CAS  Google Scholar 

  • Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141–146

    PubMed  CAS  Google Scholar 

  • Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64:7022–7029

    PubMed  CAS  Google Scholar 

  • Yu P, Rowley DA, Fu YX, Schreiber H (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18:226–231

    PubMed  CAS  Google Scholar 

  • Yuspa SH (2000) Overview of carcinogenesis: past, present and future. Carcinogenesis 21:341–344

    PubMed  CAS  Google Scholar 

  • Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H, Elmets CA (2008) Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 68:615–622

    PubMed  CAS  Google Scholar 

  • Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127

    PubMed  CAS  Google Scholar 

  • Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263–274

    PubMed  CAS  Google Scholar 

  • Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295–307

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank all those that have contributed to work discussed here but are not referenced due to space constraints. The authors acknowledge support by grants from the National Institutes of Health (NIH)/NCI (R01CA130980, R01CA132566, R01CA140943, P50CA58207), and the Department of Defense (W81XWH-06-1-0416, PR080717 to L.M.C., and grants from the Dutch Cancer Society (2006-3715 and 2011-5004), the Netherlands Organization for Scientific Research (VIDI 917.96.307), and the Association for International Cancer Research (AICR 11-0677) to K.E.d.V.

Author information

Authors and Affiliations

  1. Department of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands

    Karin E. de Visser

  2. Department of Pathology, University of California, San Francisco, 513 Parnassus Ave. HSW-450C, San Francisco, CA, 94143, USA

    Lisa M. Coussens

  3. Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 513 Parnassus Ave. HSW-450C, San Francisco, CA, 94143-0502, USA

    Lisa M. Coussens

Authors
  1. Karin E. de Visser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa M. Coussens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa M. Coussens .

Editor information

Editors and Affiliations

  1. , Laboratory Of Cancer Biology and Genetic, National Cancer Institute, Convent Dr. 37, Bethesda, 20892, Maryland, USA

    Jeffrey E. Green

  2. National Cancer Institute, Center for Cancer Research, National Institutes of Health, South Drive 50, Bethesda, 20892, Maryland, USA

    Thomas Ried

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

de Visser, K.E., Coussens, L.M. (2012). Utilizing Mouse Models of Human Cancer for Assessing Immune Modulation of Cancer Development. In: Green, J., Ried, T. (eds) Genetically Engineered Mice for Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69805-2_21

Download citation

Publish with us

Policies and ethics

Search

Navigation